Phase 1 dose escalation study of DSP107, a first-in-class CD47 and 4-1BB targeting multifunctional immune-recruitment protein, in patients with advanced solid tumors

MLA

Jason J. Luke, et al. “Phase 1 Dose Escalation Study of DSP107, a First-in-Class CD47 and 4-1BB Targeting Multifunctional Immune-Recruitment Protein, in Patients with Advanced Solid Tumors.” Journal of Clinical Oncology, vol. 40, June 2022, p. 2647. EBSCOhost, https://doi.org/10.1200/jco.2022.40.16_suppl.2647.

APA

Jason J. Luke, Anwaar Saeed, Babar Bashir, Yaffa Shwartz, Rinat Tabakman, Adam Foley-Comer, & Antonio Jimeno. (2022). Phase 1 dose escalation study of DSP107, a first-in-class CD47 and 4-1BB targeting multifunctional immune-recruitment protein, in patients with advanced solid tumors. Journal of Clinical Oncology, 40, 2647. https://doi.org/10.1200/jco.2022.40.16_suppl.2647

Chicago

Jason J. Luke, Anwaar Saeed, Babar Bashir, Yaffa Shwartz, Rinat Tabakman, Adam Foley-Comer, and Antonio Jimeno. 2022. “Phase 1 Dose Escalation Study of DSP107, a First-in-Class CD47 and 4-1BB Targeting Multifunctional Immune-Recruitment Protein, in Patients with Advanced Solid Tumors.” Journal of Clinical Oncology 40 (June): 2647. doi:10.1200/jco.2022.40.16_suppl.2647.